The leading provider of AI-powered technology for pathology.
Buy
Sign up to view historical trading trends and place an offer.
Sell
Understand share pricing, list anonymously, and benefit from transparent fees.
Overview
PathAI is a biotechnology company focused on improving patient outcomes through AI-powered pathology solutions. Founded to enhance the accuracy and efficiency of medical diagnoses, PathAI collaborates with biopharmaceutical companies, laboratories, and clinicians to provide advanced diagnostic tools.
PathAI Funding
Sign up to gain insights into PathAI funding history, including the funding round, time period, and amount raised.
| Financing Round | Date | Amount | Price per share | Valuation |
|---|---|---|---|---|
| Round | Date | Amount | PPS | Valuation |
| Series C | Apr 11, 2021 | 165M | ||
| Series B | Nov 04, 2019 | 15M | ||
| Series B | Apr 09, 2019 | 60M | ||
| Series A | Oct 18, 2017 | 11M | ||
| Series A | Oct 18, 2017 | 3M | ||
| Series A | Oct 18, 2017 | 210K | ||
| Series A | Oct 18, 2017 | 165K |
Access the PPS, Valuation details, and a wealth of other data by signing up. Source: Nasdaq Private Market
Buy
Sign up to view historical trading trends and place an offer.
Sell
Understand share pricing, list anonymously, and benefit from transparent fees.
PathAI Management Team
Investors
8VC
Adage Inc.
Biospring Management, LLC
Bristol-Myers Squibb Company
D1 Capital Partners
Danhua Capital
Danhua Capital LP
General Atlantic LLC
General Catalyst
Kaiser Permanente Ventures
Kdt Ventures
KdT Ventures
Merck Global Health Innovation Fund LLC
Pillar Companies
Polaris Partners
Refactor Capital
Tiger Global
PathAI Valuations & Financials
View real-time NPM data on PathAI stock including daily PathAI stock price estimates, valuation history, and historical share price information. Access PathAI financing rounds, secondary trade levels, cap table data, and private company comparable transactions. Use NPM's private company valuation database to track PathAI pricing across six independent market signals. Looking for private company due diligence data sources on PathAI? Get in touch to learn more.
Similar Companies
like PathAI
Cerebral
Healthcare & Life Sciences
Telemedicine mental health startup, providing evidence-based therapeutic techniques and medication management.
ArsenalBio
Healthcare & Life Sciences
Develops programmable cell therapies for cancer patients.
Eikon Therapeutics
Healthcare & Life Sciences
Uses revolutionary technology to discover novel treatments for life-threatening diseases.
Kallyope
Healthcare & Life Sciences
Biotech company developing therapies targeting gut-brain axis interactions to treat metabolic and neurological diseases.
Neuron23
Healthcare & Life Sciences
Biotechnology company focused on developing personalized medicines for genetic disorders.
Noah Medical
Healthcare & Life Sciences
Develops robotic platforms and technologies aimed at early diagnosis and treatment across multiple medical indications.
Retro Biosciences
Healthcare & Life Sciences
Cutting-edge science and technology that is specifically targeting the epigenetic mechanisms of aging.
ReCode Therapeutics
Healthcare & Life Sciences
Developing precision medicines for genetic respiratory diseases.
FAQ
We have answers
PathAI stock does not trade on public stock exchanges. PathAI stock is considered a private security and you need to be an accredited investor to trade shares. To invest in PathAI stock you can either buy shares directly through the company or work with a secondary trading marketplace like Nasdaq Private Market.
Learn more about the secondary market for private company shares on the investors page.
PathAI Stock does not trade on public stock exchanges. In order to sell PathAI shares you need to work directly with the company or with a secondary trading marketplace like Nasdaq Private Market. NPM has more than a decade of experience helping sell shares on the private market to our network of institutional investors.
Learn more about NPM services for selling privately held stock on the Employee Shareholders page.
Read more about how to sell private company stock on the private secondary market:
PathAI does not have a publicly available stock price because it is privately held and not traded on public stock exchanges. Through the NPM Data and Intelligence database from Nasdaq Private Market, you can view PathAI share price and other valuable private market data.
Read more about secondary market private company stock prices:
There is no ticker symbol for PathAI stock because it is a private company. Private companies do not have ticker symbols like public companies, they are identified primarily by using the company ‘street’ name or legal name.
Nasdaq Private Market currently works with employees, ex-employees, and other company investors. In order to sell PathAI stock you need to receive the company’s approval, which Nasdaq Private Market manages on your behalf.
Learn more about selling privately held stock on the Employee Shareholders page.
Read more about how to sell shares of a private company and eligibility for selling privately held stock:
Currently, Nasdaq Private Market only works with accredited entities and institutional investors to purchase private company stock. In order to invest in PathAI stock, you need to be an accredited entity or institutional investor.
Learn more about the Nasdaq Private Market tool kit for investors on the Investor Trading page.
Once you buy or sell, stock share ownership must transfer before funds are wired. With Nasdaq Private Market, clients leverage our patent-pending Transfer and Settlement technology which streamlines and manages transfer activity from match to settlement.
To learn more about private company stock Transfer and Settlement, check out the Transfer and Settlement page.
PathAI is a private company and has not had an IPO. There is currently no PathAI IPO price. Get started to begin exploring the Nasdaq Private Market Data and Intelligence database and gain access to actionable data related to PathAI IPO.
Learn more about Data and Intelligence private company stock data for institutional investors on the on the NPM Data and Intelligence Product Page.
